Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP562110.RAvBZnQPt-97vt1TKzEFVUJ-TegjNzRO7M5hin2h6JFXg130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP562110.RAvBZnQPt-97vt1TKzEFVUJ-TegjNzRO7M5hin2h6JFXg130_assertion type Assertion NP562110.RAvBZnQPt-97vt1TKzEFVUJ-TegjNzRO7M5hin2h6JFXg130_head.
- NP562110.RAvBZnQPt-97vt1TKzEFVUJ-TegjNzRO7M5hin2h6JFXg130_assertion description "[Up till now EGFR gene mutations, KRAS gene mutations and EML4-ALK fusion genes are the most widely recognized alterations involved in both the biology and the clinical management of lung adenocarcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP562110.RAvBZnQPt-97vt1TKzEFVUJ-TegjNzRO7M5hin2h6JFXg130_provenance.
- NP562110.RAvBZnQPt-97vt1TKzEFVUJ-TegjNzRO7M5hin2h6JFXg130_assertion evidence source_evidence_literature NP562110.RAvBZnQPt-97vt1TKzEFVUJ-TegjNzRO7M5hin2h6JFXg130_provenance.
- NP562110.RAvBZnQPt-97vt1TKzEFVUJ-TegjNzRO7M5hin2h6JFXg130_assertion SIO_000772 21129606 NP562110.RAvBZnQPt-97vt1TKzEFVUJ-TegjNzRO7M5hin2h6JFXg130_provenance.
- NP562110.RAvBZnQPt-97vt1TKzEFVUJ-TegjNzRO7M5hin2h6JFXg130_assertion wasDerivedFrom befree-20140225 NP562110.RAvBZnQPt-97vt1TKzEFVUJ-TegjNzRO7M5hin2h6JFXg130_provenance.
- NP562110.RAvBZnQPt-97vt1TKzEFVUJ-TegjNzRO7M5hin2h6JFXg130_assertion wasGeneratedBy ECO_0000203 NP562110.RAvBZnQPt-97vt1TKzEFVUJ-TegjNzRO7M5hin2h6JFXg130_provenance.